mCSPC
Advertisement
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
Dr. Gebrael discusses the impact of baseline bone pain on survival outcomes in mHSPC.
There is a lack of research investigating associations between bone pain and OS in patients with mHSPC.
Darolutamide plus ADT provided a clinically meaningful increase in rPFS compared with placebo plus ADT.
Dr. Lowentritt sheds light on a real-world comparison of PSA response in patients with mCSPC treated with apalutamide.
Intensified androgen blockade improves PSA progression-free survival in prostate cancer without affecting quality of life.
The ArteraAI MMAI prognostic biomarker performs risk stratification of patients with localized prostate cancer.
Researchers evaluated differences in treatment intensification and overall survival between patient groups.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
A combination of androgen annihilation therapy with radiotherapy was tested for recurrent metastatic prostate cancer.
Investigators evaluated the data of 427 patients with metastatic HSPC and serum initial PSA greater than 100 ng/ml.
Dr. Aggarwal also discusses next steps regarding the intensification of ADT in patients with BRPC.
Phase III mHSPC trials can take up to a decade to complete when OS is used as the primary endpoint.
The addition of apalutamide to ADT should be considered in patients with high-risk BRPC, according to researchers.
Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.
Researchers evaluated real-world survival for patients with mCSPC who received enzalutamide or apalutamide treatment.
Researchers noted a lack of research surrounding treatment-related adverse events in these patients.
Drs. Shen and Graff discuss patient outcomes from TITAN and SPARTAN, as well as assessing functional vs chronological age.
Compared with ADT alone, apalutamide plus ADT had a favorable hazard ratio across all end points regardless of age.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.